Tuesday, January 09, 2018
Intec Pharma Ltd., a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced it has entered into a Feasibility and Option agreement with Novartis Pharmaceuticals to explore using the Accordion Pill platform for a proprietary Novartis compound. The details of the therapeutic area or specific compound were not released. Following potentially successful feasibility studies including a Phase 1 PK study, Novartis has the option to enter into negotiations with respect to a potential licensing agreement for employing Intec Pharma Accordion Pill™ technology.
"We are delighted to work with Novartis in potentially utilizing our Accordion Pill platform technology," said Jeffrey A. Meckler, Chief Executive Officer of Intec Pharma. "Over the past few years, the Accordion Pill has demonstrated impressive clinical results in applications for drugs with both a narrow absorption window and poor solubility. As the company grows, we hope to increase the number of partners who ask us to formulate Accordion Pills for their proprietary compounds."
